

May 25, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attention: Tyler Howes

**Re: BELITE BIO, INC.**  
**Registration Statement on Form F-3**  
**Filed May 22, 2023**  
**File No. 333-272125**

Ladies and Gentlemen:

Pursuant to Rules 460 and 461 of the Rules and Regulations of the U.S. Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended, Belite Bio, Inc (the "**Company**"), hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-3 (the "**Registration Statement**") be accelerated to, and that the Registration Statement become effective at, 9:00 AM (Eastern time) on May 30, 2023, or as soon thereafter as practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Robert Plesnarski (+1 (202) 383-5149) or Portia Ku (+1 (212) 326-2168) of O'Melveny & Myers LLP, counsel to the Company. Thank you for your assistance with this matter.

*[Signature page follows]*

---

Very truly yours,

BELITE BIO, INC

By: /s/ Yu-Hsin Lin

---

Name: Yu-Hsin Lin

Title: Chief Executive Officer and Chairman

---